Japson Pharmaceuticals (Pb) Profile
Key Indicators
- Authorised Capital ₹ 8.00 M
as on 29-06-2024
- Paid Up Capital ₹ 6.50 M
as on 29-06-2024
- Company Age 41 Year, 4 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 7.25 M
as on 29-06-2024
- Satisfied Charges ₹ 34.85 M
as on 29-06-2024
- Revenue -100.00%
(FY 2021)
- Profit -101.36%
(FY 2021)
- Ebitda 11.30%
(FY 2021)
- Net Worth -0.18%
(FY 2021)
- Total Assets %
(FY 2021)
About Japson Pharmaceuticals (Pb)
The Company is engaged in the Healthcare Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 8.00 M and a paid-up capital of Rs 6.50 M.
The company currently has active open charges totaling ₹7.25 M. The company has closed loans amounting to ₹3.49 Cr, as per Ministry of Corporate Affairs (MCA) records.
Pervesh Bir, Abhay Barnala, and Angad Pratap serve as directors at the Company.
- CIN/LLPIN
U24232CH1983PLC005474
- Company No.
005474
- Company Classification
Public Limited Indian Non-Government Company
- Incorporation Date
16 Jun 1983
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Chandigarh
Industry
Company Details
- Location
Chandigarh, Chandigarh, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Japson Pharmaceuticals (Pb)?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Pervesh Bir | Additional Director | 25-Jan-2024 | Current |
Abhay Barnala  | Director | 03-May-2019 | Current |
| Angad Pratap | Director | 03-May-2019 | Current |
Financial Performance and Corporate Structure Insights of Japson Pharmaceuticals (Pb).
Japson Pharmaceuticals (Pb) Limited, for the financial year ended 2021, experienced significant reduction in revenue, with a 100% decrease. The company also saw a substantial fall in profitability, with a 101.36% decrease in profit. The company's net worth dipped by a decrease of 0.18%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations | |||||||
| Total Assets | |||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Japson Pharmaceuticals (Pb)?
In 2021, Japson Pharmaceuticals (Pb) had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Sbi Creation Date: 02 Feb 1987 | ₹3.10 M | Open |
S B C Creation Date: 17 Aug 1985 | ₹4.15 M | Open |
State Bnak Of India Creation Date: 20 Jan 1988 | ₹1.45 M | Satisfied |
How Many Employees Work at Japson Pharmaceuticals (Pb)?
Unlock and access historical data on people associated with Japson Pharmaceuticals (Pb), such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Japson Pharmaceuticals (Pb), offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Japson Pharmaceuticals (Pb)'s trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
_PRIVATE_LIMITED_354462.webp){kind=small}
